To access this element change to forms mode OFF
Grant Award View - GA91748
Manufacturing consortium for cancer radioimmunotherapy
GA ID:
GA91748
Agency:
Department of Industry, Science and Resources
Approval Date:
18-Jun-2020
Publish Date:
8-Jul-2020
Category:
Industry Innovation
Grant Term:
7-Jul-2020 to 7-Dec-2024
Original: 7-Jul-2020 to 30-Jun-2023
Value (AUD):
$3,300,000.00
(GST inclusive where applicable)
Variations:
- GA91748-V1 - Extending end date (25-Jan-2023 )
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DISR 20/21 Investing in science, technology and commercialisation
Grant Program:
Cooperative Research Centres Programme
Grant Activity:
Manufacturing consortium for cancer radioimmunotherapy
Purpose:
GlyTherix is an Australian SME developing antibody treatments for cancer. Radioimmunotherapy (RIT) uses antibodies to selectively deliver radiation to kill cancer cells, while limiting damage to healthy cells. Despite its tremendous potential, widespread adoption of RIT has been limited by the complex manufacturing process and short shelf life of the radioscope. This project brings together Australian SME's, Universities and Government research organisations CSIRO and ANSTO to pioneer manufacturing of "shake-and-bake" kits that allow on-site, on-demand production of RITs in hospital radiopharmacies. Miltusimab antibody will be used as a testbed for the entire production process and testing safety and efficacy in a Phase 1 clinical trial.
GO ID:
GO Title:
Cooperative Research Centres Projects (CRC-P) Grants - Round 9
Internal Reference ID:
CRCPIX000142
Selection Process:
Open Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
GLYTHERIX LTD
Recipient ABN:
66 621 291 996
Grant Recipient Location
Suburb:
MACQUARIE PARK
Town/City:
MACQUARIE PARK
Postcode:
2113
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
2113
Country:
AUSTRALIA